Osteopore Limited announced that it has signed a Collaboration Agreement with Livingstone Health Holding Limited (Livingstone Health), to jointly develop new applications and products for regenerating bone and tissue. Under the Collaborative Agreement, Livingstone Health's highly experienced surgeons will work closely with Osteopore to jointly develop products, solutions and therapies for bone and tissue regeneration using Osteopore's bioresorbable implants. Osteopore's implants dissolve over time to leave only natural healthy bone, and have largely outperformed traditional implant methods in terms of design, post-surgery complications and associated long-term health care costs. Surgeons from Livingstone Health will apply new and existing Osteopore implants in a clinical setting for orthopaedic procedures. The first being Osteomesh®, a rigid yet flexible bioresorbable scaffold, which will be used for tendon repair, including rotator cuff and
Achilles tendon. To date, Osteomesh® has been used in cranial (skull) and orbital (eye) reconstruction, as well as in rhinoplasty, as a cartilage support. The partnership with Livingstone Health will enable the expansion of the Osteomesh® in tendon repair, and this will be the first time the products are used for orthopaedic applications in Singapore. The second is an entirely new Osteopore product, a synthetic fibular strut graft, which will be used for bone reconstruction in the upper and lower limbs. The synthetic fibular strut will reduce the need to harvest bone from the fibula (shin bone), avoiding additional procedures and associated complications. Both of these procedures form part of Osteopore's strategy to not only develop new products, but also uncover new potential applications using its existing commercially available implants. This is a key step in expanding the commercial use of Osteopore's platform technology and will provide Osteopore with important patient data to further support regulatory clearances, market adoption and penetration in Singapore and beyond.